[HTML][HTML] Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM) …
Introduction: Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …
[引用][C] Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM …
MA Dimopoulos, DJ White, L Benboubker, G Cook… - …, 2017 - scholarworks.bwise.kr
ScholarWorks@SUNGKYUNKWAN UNIVERSITY: Daratumumab, Lenalidomide, and
Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or …
Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or …
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) …
MA Dimopoulos, DJ White, L Benboubker, G Cook… - 2017 - ashpublications.org
Introduction: Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …
[PDF][PDF] Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM …
MA Dimopoulos - cms.cws.net
ASH PowerPoint Template 2016 16-9ratio DARKER (11.14.16).pptx Page 1 Daratumumab,
Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) …
Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) …
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) …
MA Dimopoulos, DJ White, L Benboubker, G Cook… - 2017 - ashpublications.org
Introduction: Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …